Cystic Fibrosis Foundation’s Post

Partnering directly with the communities you serve is not only inspiring, it’s necessary to make the best decisions.

This is something I'm very passionate about. Lets do more than simply 'hope' for health equity. Read below to find out more about the actions we can take. #healthcare #diversity #equity #inclusion

Attend the #DEI Workshop, Transforming Transplantation: Building Paths to Equitable Care and Outcomes in Prague. 💡 This interactive session will explore the factors that influence and interfere with equitable access to #transplantation and post-txp care for patients. The workshop will feature: - Historical and present forms of systemic bias and structural racism - Multi-disciplinary research studies for multiple organs and countries - Active discussions and presentations - Panel of experts to present tools that practitioners can use to recognize and address systemic issues Register now to gain insights into how to advocate for patients and help empower patients throughout their transplant journey. Learn more at 🔗 https://bit.ly/3SE8c9n

Let's connect, collaborate, and make a positive impact at #SScWorldCongress 📌 Don't miss your chance to schedule a meeting with Dr. Olga Kubassova and Prof. Francesco Del Galdo at the 8th World Congress of Systemic Sclerosis, in Prague this week! Over the past several years, our team of experts has played a pivotal role in conducting clinical studies and research projects focused on finding new therapies for scleroderma patients. #Prague2024 #SclerodermaResearch #clinicalresearch #clinicaltrials

Today is World Clinical Trial day. There are many trailblazers of clinical development, but we must not fail to recognize the bold choice made by patients to contribute to the next era of science. The costs to participate can include time, money, and on occasion health, including ending an active treatment to comply with clinical protocol. Patients are as much the trailblazers as the clinical, industry and academic teams who shape research & development. On this day I am reminded of how important inclusivity and diversity of thought are, to continue to break through disease barriers to develop new treatments and hopefully the cures of the future. Read more here: https://lnkd.in/eAfSqQnG

Have you checked out the latest funding opportunities from the National Health and Medical Research Council (NHMRC)? Here are a few that are currently on offer 👇 💡 2024 Novel Treatments and Management Strategies for Chronic Pain Grant Opportunity (GO7061) The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by developing effective approaches for treating people with chronic pain. Applications close: 6 November 2024 (min. data due 9 October) Learn more: https://lnkd.in/gUwyyc86 🧠 NHMRC-CIHR Canadian Consortium on Neurodegeneration in Aging (CCNA): Indigenous Health Research (GO7114) NHMRC will support up to 2 Canadian-Australian collaborative teams undertaking research that advances the field of research in any of the recognised forms of dementia, specifically in Indigenous populations. Applications close: 12 December 2024 (min. data due 6 November) Learn more: https://lnkd.in/g8F_Pc3p 🔬 MRFF – 2024 Clinical Trials Activity Grant Opportunity (GO7146) The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by investing in new clinical trials that support increased access to high-quality, evidence-based and effective health care. Applications close: 2 April 2025 (min. data due 5 March 2025) Learn more: https://lnkd.in/gbx2jPXc See more funding opportunities: https://lnkd.in/g6_VGWGs

This article is worth the time. Everything about this article sets the tone for what clinical research should aspire to in 2024, as achieved by Genentech and outlined within the article by Quita Beeler Highsmith, MBA. As a clinician, I have always believed our healthcare system does not have to be a monolith when it comes to health disparities and inequities, especially in the presence of science-bending feats that anyone willing (and clinically fit) should have access to and the opportunity to participate in should they choose. The data is very clear on the fact that when we engage diverse populations about clinical trials, enrollment rates are similar to non-diverse candidates. The data is also clear that diverse patients are not engaged at equal measure as their counterparts, often due to implicit, and sadly, in some cases, explicit bias. As such, it is incumbent that those working toward bridging the disparities gap observed in healthcare and trial research continue to keep our foot on the gas. Great strides are being made and will continue to do so with sustained effort and commitment.

🔬 The wait for effective treatments is agonizing for patients with rare and life-threatening diseases. A research conducted by Merkel et al. (2016) highlights their unmet needs: delayed diagnosis, limited treatment options, and significant impact on quality of life. As leaders, we can change this narrative. Collaboration with patient advocacy groups (PAGs), innovators, and investigators is key. 🤝 Why Partner? 👥 Patient Advocacy Groups: They understand patient experiences, shaping research priorities. 🔬 Investigators & Innovators: Their expertise drives the creation of new therapies. Success Story: The RDCRN Model A real-world example: The Rare Diseases Clinical Research Network (RDCRN) proves collaboration works. Here's how: ✅ Early Patient Involvement: Including patients from the start leads to better studies. 📢 Communication and Outreach: Patient groups excel at educating patients and boosting trial participation. 💰 Funding and Prioritization: They can influence research focus and even fund specific projects. 📚 Education and Dissemination: Collaboration ensures clear, accessible materials for patients and families. 🚀 Faster Recruitment: Patient groups are the #1 source for clinical trial referrals. The Impact: RDCRN shows stronger, faster research due to investigator-patient partnerships. Let's join forces! By prioritizing collaboration and patient-centered approaches, we can make a real difference. #RareDiseases #ClinicalTrials #Partnerships #PatientAdvocacy

If you had an opportunity to read the article I published for International Women’s Day, you know how passionate I am about designing clinical trials that are representative of the patient populations we aim to treat at AstraZeneca. We recently published an analysis in Contemporary Clinical Trials that examines patient diversity in AstraZeneca’s clinical trials in the US.   Congratulations and thank you to Serban Ghiorghiu, Claudia Cabrera, Victoria L Chiou, MD, Barbara Valastro and the full team for the work you are doing in this space. This study is just one example of the systemic approach we are taking to evaluating our clinical trials to improve diversity as we bring innovative medicines to patients. There is still much work to be done to remove data gaps and improve access to clinical trials – a relentless focus on patients, engagement with patient advocacy groups and use of digital tools to reduce the burden on patients who join clinical trials are all needed to make more progress.  https://lnkd.in/eT3ep5TS  #Diversity #STEM